Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): February 27, 2019
|
CORMEDIX
INC.
|
|
(Exact
Name of Registrant as Specified in Charter)
|
|
Delaware
|
|
001-34673
|
|
20-5894890
|
|
(State
or Other Jurisdictionof Incorporation)
|
|
(CommissionFile
Number)
|
|
(IRS
EmployerIdentification No.)
|
|
400
Connell Drive, Suite 5000,
Berkeley
Heights, NJ
|
07922
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain
Officers; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On
February 27, 2019, our Board of Directors appointed Alan W. Dunton,
M.D., as a director, effective March 1, 2019, to serve until the
2019 annual meeting or until his respective successor is duly
elected and qualified.
In
2006, Dr. Duncan founded Danerius, LLC, a biotechnology and
pharmaceutical consulting business. Prior to starting Danerius, he
was Chief Executive Officer of Panacos Pharmaceuticals, Inc., as
well as Metaphore Pharmaceuticals, Inc., both biotechnology
companies. He was also President and Managing Director of the
Janssen Research Foundation, the research and development and
regulatory arm of the pharmaceuticals division at Johnson and
Johnson. Dr. Dunton received his Bachelor of Science degree in
biochemistry, magna cum laude, from State University of New York at
Buffalo, and received his M.D. from New York University School of
Medicine.
There
are no arrangements or understandings between Dr. Dunton and any
other person pursuant to which he was appointed as a director of
our Board and there are no related party transactions between Dr.
Dunton and our company.
Item
8.01. Other Events.
On
March 4, 2019, we issued a press release to report the appointment
of the director identified in Item 5.02. A copy of the release is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press
release of CorMedix Inc. issued March 4, 2019.
|
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX
INC.
|
|
|
|
|
|
|
|
Date: March 4,
2019
|
By:
|
/s/ Robert W.
Cook
|
|
|
|
|
Name: Robert
W. Cook
|
|
|
|
|
Title: Chief
Financial Officer
|
|